Annovis Bio Inc.

Malvern, PA

UEI
LS3NJ5K64FH8
CAGE
5CUG6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
101 Lindenwood Dr #225, Malvern, PA 19355, USA
Website
annovisbio.com
Founded
2008
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Long-term toxicology studies for posiphen; 6 month in rats and 9 months in dogs U01AG056437 National Institute on Aging (NIH) $1,929,278
Development of posiphen, an inhibitor of phosphorylated TAU expression, as a treatment of TBI W81XWH1320092 Medical Command (Army) $1,223,102
Development of the novel small molecule drug posiphen to treat traumatic brain in… R43NS083080 National Institutes of Health -$349,999
Small molecule inhibitor of amyloid precursor protein synthesis R43AG037247 National Institutes of Health $213,508

Quick answers

Is Annovis Bio Inc. registered in SAM.gov?

Yes. Annovis Bio Inc.'s SAM.gov registration is active through May 12, 2027.

What is Annovis Bio Inc.'s most recent federal award?

Annovis Bio Inc.'s most recent federal grant award is Long-term toxicology studies for posiphen; 6 month in rats and 9 months in dogs (U01AG056437), from National Institute on Aging (NIH), on September 15, 2019.

On GovTribe

See Annovis Bio Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login